reference/27109194

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/27109194

Outgoing Links

Predicate	Object
contentType	Journal Article\|Research Support, Non-U.S. Gov't
issn	1932-6203
issueIdentifier	4
pageRange	e0231828-
publicationName	PLOS ONE
startingPage	e0231828
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_2deed1e38cd8a78ccf991074a7d2443a
bibliographicCitation	Kirino S, Tsuchiya K, Kurosaki M, Kaneko S, Inada K, Yamashita K, Osawa L, Hayakawa Y, Sekiguchi S, Okada M, Wang W, Higuchi M, Takaura K, Maeyashiki C, Tamaki N, Yasui Y, Nakanishi H, Itakura J, Takahashi Y, Asahina Y, Izumi N. Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma. PLoS ONE. 2020 Apr 20;15(4):e0231828. doi: 10.1371/journal.pone.0231828.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_cd01e26077bbf5d93b250df49dd854e1 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5ed6c8a4e9fbec2ebe20516d95955352 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0003-2660-6580 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_26e8dfb5429e93a402188a0640bc8c7d http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_037d71dc5ae2ccce2e1a820a1c2d7183 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_776ebbd39085745338f924cb82c38eb7 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2c78d3ab81912f820d8b149edfb1f411 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_97faeb4f8dbc4b733ebbea22a30d3e5a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_cf73ee266bc955aa4739ce4c286d7fc0 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_fa2d24ed2fc63d6be6003c292b5b7cb0 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_cefae10e8abaff61db350977359dc03b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_841a2f89d90ac24ae5beebb196524d8e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_24a107590e5e4bbc0c00f0c7a7810eca http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_cdcc45c43759de020bc1f72be1910b29 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b7fa944fd7e2e797d4e193c9025c0e9a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_024c49e372b2f1c09f0c899e79614d36 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ad0ea432e5c5882a348a3ddd250de4a6 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6d745232dc9c673d96f4de702303052f http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-0055-8229 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-6117-4990 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0003-4634-6616 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2a98fa26b25bfba19fc20adc1d2ac71f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f235a5221f442b11184cd18a6be24a6f
date	2020-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://doi.org/10.1371/journal.pone.0231828 https://pubmed.ncbi.nlm.nih.gov/32310967 https://pubmed.ncbi.nlm.nih.gov/PMC7170221
isPartOf	http://rdf.ncbi.nlm.nih.gov/pubchem/journal/33103 https://portal.issn.org/resource/ISSN/1932-6203
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma
discusses	http://id.nlm.nih.gov/mesh/M0575909 http://id.nlm.nih.gov/mesh/M0018350 http://id.nlm.nih.gov/mesh/M0001483 http://id.nlm.nih.gov/mesh/M0016578
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D008113Q000188 http://id.nlm.nih.gov/mesh/D006528Q000188 http://id.nlm.nih.gov/mesh/D010671Q000627 http://id.nlm.nih.gov/mesh/D000970Q000627 http://id.nlm.nih.gov/mesh/D011804Q000627
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D016019 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D010671Q000008 http://id.nlm.nih.gov/mesh/D010671Q000009 http://id.nlm.nih.gov/mesh/D000970Q000009 http://id.nlm.nih.gov/mesh/D000970Q000008 http://id.nlm.nih.gov/mesh/D011804Q000008 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D004305 http://id.nlm.nih.gov/mesh/D011804Q000009 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D000369 http://id.nlm.nih.gov/mesh/D000368 http://id.nlm.nih.gov/mesh/D006528Q000473 http://id.nlm.nih.gov/mesh/D008113Q000473
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_73717aafac1e7701dab0fa02b8936926 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9823820 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7998

Total number of triples: 70.